Trajectories of serum hepatitis B surface antigen predict HBeAg clearance in treated children with chronic hepatitis B

Background The association between the early dynamics of hepatitis B surface antigen (HBsAg) and its subsequent clearance has been observed in patients with chronic hepatitis B (CHB). However, its relationship with other clinical outcomes remains poorly understood. Objective This study aimed to investigate the longitudinal trajectories patterns of HBsAg and their associations with hepatitis B e antigen (HBeAg) clearance in pediatric patients with CHB undergoing antiviral treatment. Methods A large retrospective cohort study was conducted on 402 pediatric patients with HBeAg-positive CHB. Latent class trajectory models (LCTM) were applied to examine HBsAg trajectories within the first six months of initiating antiviral therapy. Cox proportional hazard models were used to assess the associations between HBsAg trajectories and HBeAg clearance. Results Among the 402 participants, the median age was 5 years, with 249 (61.94%) being male. During a median follow-up of 19.03 months, 216 participants (53.73%) achieved HBeAg clearance. LCTM revealed three distinct HBsAg trajectory patterns: ‘trajectory 1’ (sustained stability, n=43, 10.7%), ‘trajectory 2’ (slow decline, n=195, 48.5%), and ‘trajectory 3’ (rapid decline, n=164, 40.8%). Patients in trajectories 2 and 3 had significantly higher probabilities of HBeAg clearance compared to those in trajectory 1 (adjusted hazard ratio [aHR] = 3.99, 95% CI, 2.20-7.22 for trajectory 2; aHR = 7.21, 95% CI, 3.65-14.24 for trajectory 3). Conclusions There is significant heterogeneity in the longitudinal changes of HBsAg levels among pediatric CHB patients with antiviral treatment. Approximately half of the patients exhibited a substantial HBsAg decline, which was associated with a higher likelihood of HBeAg clearance.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-16
DOI
https://doi.org/10.3389/fimmu.2026.1995382
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Trajectories of serum hepatitis B surface antigen predict HBeAg clearance in treated children with chronic hepatitis B

Wenxian Ouyang, Zhenzhen Yao, Zhe Ji, Songxu Peng
3 links
Frontiers in Immunology
Hepatitis B Virus Studies
article

Trajectories of serum hepatitis B surface antigen predict HBeAg clearance in treated children with chronic hepatitis B

Wenxian Ouyang, Zhenzhen Yao, Zhe Ji, Songxu Peng
article en

Abstract

Background The association between the early dynamics of hepatitis B surface antigen (HBsAg) and its subsequent clearance has been observed in patients with chronic hepatitis B (CHB). However, its relationship with other clinical outcomes remains poorly understood. Objective This study aimed to investigate the longitudinal trajectories patterns of HBsAg and their associations with hepatitis B e antigen (HBeAg) clearance in pediatric patients with CHB undergoing antiviral treatment. Methods A large retrospective cohort study was conducted on 402 pediatric patients with HBeAg-positive CHB. Latent class trajectory models (LCTM) were applied to examine HBsAg trajectories within the first six months of initiating antiviral therapy. Cox proportional hazard models were used to assess the associations between HBsAg trajectories and HBeAg clearance. Results Among the 402 participants, the median age was 5 years, with 249 (61.94%) being male. During a median follow-up of 19.03 months, 216 participants (53.73%) achieved HBeAg clearance. LCTM revealed three distinct HBsAg trajectory patterns: ‘trajectory 1’ (sustained stability, n=43, 10.7%), ‘trajectory 2’ (slow decline, n=195, 48.5%), and ‘trajectory 3’ (rapid decline, n=164, 40.8%). Patients in trajectories 2 and 3 had significantly higher probabilities of HBeAg clearance compared to those in trajectory 1 (adjusted hazard ratio [aHR] = 3.99, 95% CI, 2.20-7.22 for trajectory 2; aHR = 7.21, 95% CI, 3.65-14.24 for trajectory 3). Conclusions There is significant heterogeneity in the longitudinal changes of HBsAg levels among pediatric CHB patients with antiviral treatment. Approximately half of the patients exhibited a substantial HBsAg decline, which was associated with a higher likelihood of HBeAg clearance.

Frontiers in ImmunologyVol. 17
Tongji University (CN), Central South University (CN), Hunan Children's Hospital (CN)
Good health and well-being
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon